The stock of Qiagen NV (QGEN) has gone up by 3.98% for the week, with a -7.91% drop in the past month and a -8.51% drop in the past quarter. The volatility ratio for the week is 1.54%, and the volatility levels for the past 30 days are 1.74% for QGEN. The simple moving average for the past 20 days is 1.00% for QGEN’s stock, with a -8.29% simple moving average for the past 200 days.
Is It Worth Investing in Qiagen NV (NYSE: QGEN) Right Now?
The price-to-earnings ratio for Qiagen NV (NYSE: QGEN) is 107.48x, which is above its average ratio. Moreover, the 36-month beta value for QGEN is 0.67. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 4 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for QGEN is 216.21M and currently, short sellers hold a 1.46% of that float. On March 06, 2025, QGEN’s average trading volume was 1.12M shares.
QGEN) stock’s latest price update
The stock of Qiagen NV (NYSE: QGEN) has increased by 3.58 when compared to last closing price of 38.55.Despite this, the company has seen a gain of 3.98% in its stock price over the last five trading days. businesswire.com reported 2025-03-06 that GERMANTOWN, Md. & VENLO, Netherlands–(BUSINESS WIRE)—- $QGEN #QIAGEN–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This marks QIAGEN’s second FDA clearance of a QIAstat-Dx panel in 2025, and builds on the authorization of five panels for use on the QIAstat-Dx system within the last 10 mont.
Analysts’ Opinion of QGEN
Many brokerage firms have already submitted their reports for QGEN stocks, with Robert W. Baird repeating the rating for QGEN by listing it as a “Neutral.” The predicted price for QGEN in the upcoming period, according to Robert W. Baird is $42 based on the research report published on February 19, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see QGEN reach a price target of $48. The rating they have provided for QGEN stocks is “Equal-Weight” according to the report published on January 06th, 2025.
Jefferies gave a rating of “Buy” to QGEN, setting the target price at $54 in the report published on December 10th of the previous year.
QGEN Trading at -6.83% from the 50-Day Moving Average
After a stumble in the market that brought QGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.68% of loss for the given period.
Volatility was left at 1.74%, however, over the last 30 days, the volatility rate increased by 1.54%, as shares sank -9.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.58% lower at present.
During the last 5 trading sessions, QGEN rose by +3.78%, which changed the moving average for the period of 200-days by -15.76% in comparison to the 20-day moving average, which settled at $39.53. In addition, Qiagen NV saw -10.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QGEN starting from Sackers Roland, who proposed sale 25,000 shares at the price of $46.00 back on Sep 11 ’24. After this action, Sackers Roland now owns shares of Qiagen NV, valued at $1,150,000 using the latest closing price.
Stock Fundamentals for QGEN
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.5 for the gross margin
The net margin for Qiagen NV stands at 0.04. The total capital return value is set at 0.02. Equity return is now at value 2.27, with 1.42 for asset returns.
Based on Qiagen NV (QGEN), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at 0.48. The debt to equity ratio resting at 0.39. The interest coverage ratio of the stock is 3.09.
Currently, EBITDA for the company is 702.07 million with net debt to EBITDA at 2.02. When we switch over and look at the enterprise to sales, we see a ratio of 4.77. The receivables turnover for the company is 5.66for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.61.
Conclusion
To wrap up, the performance of Qiagen NV (QGEN) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
